Osivax, a Lyon, France-based biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, closed its Series B financing, raising €10M from new and existing investors.
Backers included Meiji Seika Pharma.
The company intends to use the funds to accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates.
Led by CEO Alexandre Le Vert, Osivax is a clinical-stage biopharmaceutical company leveraging its self-assembling nanoparticle platform technology, oligoDOMTM, to develop pan-respiratory virus vaccines generating T-cell responses in addition to sustained B-cell responses. It is offering its broad-spectrum influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data.
Commenting on the news, Alexandre Le Vert said: “We are gaining significant momentum in advancing Osivax’s development strategy, and we are thrilled to welcome Meiji Seika Pharma as a new investor. Their support, alongside that of our existing investors, reinforces our shared ambition to transform the prevention of respiratory infectious diseases.”
FinSMEs
04/03/2025